HomeCompareGILD vs CQP

GILD vs CQP: Dividend Comparison 2026

GILD yields 2.34% · CQP yields 4.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CQP wins by $36.5K in total portfolio value
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
CQP
CQP
● Live price
4.92%
Share price
$67.12
Annual div
$3.30
5Y div CAGR
25.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$65.7K
Annual income
$12,645.22
Full CQP calculator →

Portfolio growth — GILD vs CQP

📍 CQP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDCQP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + CQP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
CQP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
CQP
Annual income on $10K today (after 15% tax)
$417.91/yr
After 10yr DRIP, annual income (after tax)
$10,748.44/yr
At 15% tax rate, CQP beats the other by $9,375.77/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + CQP for your $10,000?

GILD: 50%CQP: 50%
100% CQP50/50100% GILD
Portfolio after 10yr
$47.4K
Annual income
$7,130.06/yr
Blended yield
15.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
CQP
Analyst Ratings
3
Buy
5
Hold
10
Sell
Consensus: Sell
Price Target
$47.50
-29.2% upside vs current
Range: $44.00 — $55.00
Altman Z
2.4
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
CQP buys
0
No recent congressional trades found for GILD or CQP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDCQP
Forward yield2.34%4.92%
Annual dividend / share$3.19$3.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%25.3%
Portfolio after 10y$29.1K$65.7K
Annual income after 10y$1,614.90$12,645.22
Total dividends collected$7.6K$39.5K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuySell
Analyst price target$158.71$47.50

Year-by-year: GILD vs CQP ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrCQP PortfolioCQP Income/yrGap
1← crossover$10,974$274.45$11,316$616.05$342.00CQP
2$12,073$330.19$12,925$816.35$852.00CQP
3$13,316$398.20$14,921$1,091.85$1.6KCQP
4$14,730$481.49$17,442$1,476.10$2.7KCQP
5$16,345$583.87$20,683$2,020.55$4.3KCQP
6$18,199$710.26$24,937$2,805.86$6.7KCQP
7$20,340$866.96$30,644$3,961.48$10.3KCQP
8$22,826$1,062.22$38,490$5,700.69$15.7KCQP
9$25,731$1,306.80$49,569$8,384.84$23.8KCQP
10$29,147$1,614.90$65,684$12,645.22$36.5KCQP

GILD vs CQP: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

CQPStock

Cheniere Energy Partners, L.P., through its subsidiaries, owns and operates natural gas liquefaction and export facility at the Sabine Pass liquefied natural gas (LNG) terminal located in Cameron Parish, Louisiana. The company's regasification facilities include five LNG storage tanks with an aggregate capacity of approximately 17 billion cubic feet equivalent; two marine berths that accommodate vessels with capacity of up to 266,000 cubic meters; and vaporizers with regasification capacity of approximately 4 billion cubic feet per day. It also owns a 94-mile pipeline that interconnects the Sabine Pass LNG terminal with various interstate pipelines. Cheniere Energy Partners GP, LLC serves as the general partner of the company. The company was founded in 2003 and is headquartered in Houston, Texas.

Full CQP Calculator →
📬

Get this GILD vs CQP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.